Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma

Authors

Sattva S. Neelapu, The University of Texas MD Anderson Cancer Center
Nancy L. Bartlett, Washington University School of Medicine in St. Louis
et al

Journal

Blood Advances

Publication Date

10-22-2021

Volume

5

Issue

20

First Page

4149

Last Page

4155

Document Type

Open Access Publication

DOI

10.1182/bloodadvances.2020003848

Rights and Permissions

Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, Lazaros J. Lekakis, Patrick M. Reagan, David B. Miklos, Caron A. Jacobson, Ira Braunschweig, Olalekan O. Oluwole, Tanya Siddiqi, Yi Lin, Michael Crump, John Kuruvilla, Eric Van Den Neste, Umar Farooq, Lynn Navale, Venita DePuy, Jenny J. Kim, Christian Gisselbrecht; Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. Blood Adv 2021; 5 (20): 4149–4155. doi: https://doi.org/10.1182/bloodadvances.2020003848 Copyright 2021 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Recommended Citation

Neelapu, Sattva S.; Bartlett, Nancy L.; and et al, "Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma." Blood Advances. 5, 20. 4149 - 4155. (2021).
https://digitalcommons.wustl.edu/open_access_pubs/11085